Table 1.
Studies evaluating PRP and thin endometrium
| Author | Study design | Level of evidence | Control group (n) | Intervention group (n) | Endometrium prior to intervention (mm) | Endometrium post intervention (mm) | p value | p value | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical | Chemical | Clinical | ||||||||
| Chang et al. (2015) [7] | Cohort | 3 | - | 5 | 5.9–6.6 | >7 | - | 80 | - | |
| Zahedmodarres et al. (2017) | Cohort | 3 | - | 10 | 4–6 | 7.1–7.5 | - | 40 | - | |
| Eftekhar et al. (2018) [6] | RCT | 2 | 33 | 33 | 6.09±0.47 | 8.67±0.64 | 0.001 | 32.5 | 0.091 | 0.044 |
| Chang et al. (2019) [21] | Prospective cohort | 3 | 30 | 34 | 6.32±0.54 | 7.65±0.22 | <0.05 | 44.12 | - | 0.036 |
| Kim et al. (2019) [2] | Prospective cohort | 3 | - | 20 | 4–6.8 | 4.2–9.1 | 0.070 | 30 | 0.020 | |
| Nazari et al. (2019) [9] | Double-blind RCT | 2 | 30 | 30 | 4.92±0.67 | 7.21±0.18 | <0.001 | 33.3 | 0.031 | 0.048 |
| Frantz et al. (2020) [22] | Retrospective case series | 4 | - | 21 | <5 | - | - | 66.7 | - | |
PRP platelet-rich plasma, HRT hormone replacement therapy, eSF human endometrial stromal fibroblasts, eMSC endometrial mesenchymal stem cells, BM-MSC bone marrow–derived mesenchymal stem cells, IC Ishikawa endometrial adenocarcinoma cells